[ Price : $8.95]
Janssen Pharmaceutical discontines, due to futility, its Phase 3 MACiTEPH study evaluating macitentan 75 mg in patients with chron...[ Price : $8.95]
CymaBay Therapeutics says it will seek FDA approval for seladelpar for treating adult patients with primary biliary cholangitis af...[ Price : $8.95]
Federal Register notices: FDA issues two priority review vouchers to sponsors whose recent product approvals met the criteria (rar...[ Price : $8.95]
FDA says it is working with the CDC to investigate cases of TB associated with a bone matrix product.[ Price : $8.95]
Federal Register notice: FDA releases three draft guidances that are intended to improve the predictability, consistency, and tran...[ Price : $8.95]
Federal Register notice: FDA announces a 10/31 Cellular, Tissue, and Gene Therapies Advisory Committee meeting to review a Vertex ...[ Price : $8.95]
FDA posts an update on changes being made to the 510(k) program through three draft guidances.[ Price : $8.95]
The FDA Office of New Drugs announces a two-day meeting on PET drug issues and concerns.